Press Releases | Vertex Pharmaceuticals Newsroom

Date	Title	Additional Format
Nov 08, 2004	Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- First study in HCV patients will evaluate dosing up to 14 days --	Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
Nov 01, 2004	Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -Encouraging Results Support Initiation of Phase Ib Clinical Study-	Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
Oct 25, 2004	Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update Company continues to achieve its financial and pipeline goals	Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update
Oct 18, 2004	Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients -First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor-	Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients
Sep 07, 2004	Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, September 7, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the	Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C
Jul 26, 2004	Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update --Company on Track to Achieve 2004 Milestones--	Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update
Jul 16, 2004	GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV London, UK, July 16, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the	GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV
Jul 13, 2004	Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC Bangkok, July 13, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium, formerly GW433908, or 908) in combination with abacavir and lamivudine demonstrated sustained efficacy and safety	Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC
Jul 12, 2004	Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC Bangkok, July 12, 2004 -- HIV treatment regimens containing the protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir	Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC
Jul 08, 2004	48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS 48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a	48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS
Jun 22, 2004	Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today	Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer
Jun 14, 2004	Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Cambridge, MA, June 14, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Vertex and Mitsubishi	Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries
Jun 09, 2004	Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis Research Results Presented at CF Foundation's Williamsburg Conference	Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis
Jun 08, 2004	Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, June 8, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the initiation of a Phase I clinical	Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C
May 24, 2004	Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement - New Collaboration Builds on Drug Discovery Progress at Vertex -	Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement
May 06, 2004	Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.	Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting
May 04, 2004	Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Tucson, AZ, May 4, 2004 -- New preclinical data for two proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals	Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV
Apr 26, 2004	Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Cambridge, MA, April 26, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2004.	Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress
Apr 16, 2004	Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Berlin, Germany, April 16, 2004 -- New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex	Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches
Mar 25, 2004	GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) Cambridge, MA, March 25, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary	GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)